Study of PADCEV in adults with cancer in South Korea
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study observes adults in South Korea who are already being treated with PADCEV injections for cancer. It helps doctors gather real-world information about how the drug works and how people respond to it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be an adult (18 years or older) living in South Korea.
- You must have cancer and be receiving treatment with PADCEV (enfortumab vedotin) injections.
- You cannot have any medical condition that makes PADCEV unsafe for you.
- You cannot be taking or planning to take any other experimental (investigational) medicines during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study watches for nerve problems in people getting enfortumab vedotin and pembrolizumab as their first treatment for advanced bladder cancer. It aims to understand how common these side effects are and how they affect patients.
This trial tests a new drug, PF-08634404, either by itself or together with another drug called enfortumab vedotin, for people with advanced bladder cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
This trial compares a new investigational drug called SYS6002 with an already approved treatment called PADCEV for advanced urothelial carcinoma (a type of bladder or urinary tract cancer). The goal is to see if SYS6002 can be as effective or better than PADCEV at slowing cancer growth.
This study tests a new drug called enfortumab vedotin for people whose advanced urothelial cancer (bladder or urinary tract cancer) has not responded to prior immunotherapy (checkpoint inhibitors) and platinum chemotherapy. The goal is to see how safe and effective this treatment is for Indian adults.
This trial tests a combination of two drugs (enfortumab vedotin and avelumab) as a first treatment for men with advanced or metastatic penile cancer that cannot be removed by surgery. The goal is to see if this new combination can shrink tumors and improve outcomes.
This study looks at how enfortumab vedotin, a cancer drug, affects the nerves. It aims to understand and track neuropathy (nerve damage) in people with urothelial carcinoma, so doctors can better manage side effects.
Hear when a new Urothelial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.